- NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
- Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
More ▼
Key statistics
As of last trade Neuronetics Inc (STIM:NMQ) traded at 3.50, -30.97% below its 52-week high of 5.07, set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.55 |
---|---|
High | 3.55 |
Low | 3.42 |
Bid | 3.47 |
Offer | 3.49 |
Previous close | 3.56 |
Average volume | 45.90k |
---|---|
Shares outstanding | 29.97m |
Free float | 28.08m |
P/E (TTM) | -- |
Market cap | 106.56m USD |
EPS (TTM) | -1.06 USD |
Data delayed at least 15 minutes, as of May 02 2024 18:30 BST.
More ▼